Previous close | 1.5200 |
Open | 1.5700 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 1.5700 - 1.5900 |
52-week range | 1.5700 - 1.5900 |
Volume | |
Avg. volume | N/A |
Market cap | 127.604M |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.5200 |
Earnings date | 28 Feb 2022 - 04 Mar 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.
A look at the shareholders of Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ) can tell us which group is most powerful...